Drugs / cAd3-Marburg Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03475056 | Oct 2018 → Dec 2019 | Marburg hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06620003 Comparator | Apr 2025 → Oct 2026 expected | Marburg hemorrhagic fever | Albert B. Sabin Vaccine Institute | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cAd3-Marburg vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03475056 ↗ |
| Known as | cAd3-Marburg | “The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type...” NCT03475056 ↗ |
| Modality | Vaccine | “a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg)” PMID 36709074 ↗ Jan 2023 |
| Route | Intramuscular | “given by intramuscular (IM) injection” NCT03475056 ↗ |